Physician profile
Arun Chawla
NPI 1568611630
$1,372.59
in general payments reported to CMS, 2019-2025
18 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $48.18 · 2021: $122 · 2022: $84.31 · 2023: $357 · 2024: $226 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.39 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.30 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $210.62 | 2019-2024 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $125.00 | 2023 | Lupkynis |
| Glaxosmithkline, LLC. | $122.91 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $109.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.19 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.32 | 2024-2025 | |
| Vantive US Healthcare LLC | $50.00 | 2025 | Renal - Pd |
| Calliditas Therapeutics US INC. | $46.57 | 2024-2025 | Tarpeyo |
| Vifor Pharma, INC. | $39.62 | 2021-2023 | Veltassa |
| Lilly USA, LLC | $37.56 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $33.58 | 2024-2025 | Ozempic, Wegovy |
| Horizon Therapeutics Plc | $28.83 | 2023 | Krystexxa |
| Mozarc Medical US LLC | $25.00 | 2025 | Argyle |
| Ardelyx, INC. | $17.84 | 2025 | Ibsrela |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $17.80 | 2022 | |
| Shield Therapeutics INC | $14.65 | 2025 | |
| Amgen INC. | $14.42 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.